In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method

Wendy He; Koné Kaniga; A Simon Lynch; Robert K Flamm; Todd A Davies

doi:10.1016/j.diagmicrobio.2012.08.014

In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method

Diagn Microbiol Infect Dis. 2012 Dec;74(4):417-9. doi: 10.1016/j.diagmicrobio.2012.08.014. Epub 2012 Sep 17.

Authors

Wendy He¹, Koné Kaniga, A Simon Lynch, Robert K Flamm, Todd A Davies

Affiliation

¹ Janssen Pharmaceutical Research and Development, Raritan, NJ 08869, USA. WHe8@its.jnj.com

PMID: 22995366
DOI: 10.1016/j.diagmicrobio.2012.08.014

Abstract

The applicability of Etest for synergy testing was evaluated in 100 carbapenem-nonsusceptible Pseudomonas aeruginosa isolates. Combinations of doripenem with amikacin, colistin, or levofloxacin were synergistic or additive against 67%, 31%, and 23% of isolates, respectively. The use of Etest was practical to evaluate the synergy of doripenem with other antipseudomonal agents.

MeSH terms

Anti-Bacterial Agents / pharmacology*
Colistin / pharmacology*
Drug Synergism*
Humans
Microbial Sensitivity Tests / methods
Pseudomonas Infections / microbiology
Pseudomonas aeruginosa / drug effects*
Pseudomonas aeruginosa / isolation & purification
beta-Lactam Resistance*
beta-Lactams / pharmacology*

Substances

Anti-Bacterial Agents
beta-Lactams
Colistin